[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Jusvinza; CIGB-258\r;Administration; Intravenous;Respiration; Artificial;Peptides;- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258\r;- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "14", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "14", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS. Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol). - Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS. Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol). -", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]